Brooklyn Investment Group Sells 33,932 Shares of Pfizer Inc. (NYSE:PFE)

Brooklyn Investment Group decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 72.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,737 shares of the biopharmaceutical company's stock after selling 33,932 shares during the quarter. Brooklyn Investment Group's holdings in Pfizer were worth $338,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. State Street Corp increased its holdings in shares of Pfizer by 1.2% during the third quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock worth $8,405,930,000 after purchasing an additional 3,405,539 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Pfizer by 11.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after acquiring an additional 12,864,343 shares during the period. Geode Capital Management LLC lifted its position in shares of Pfizer by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock valued at $3,392,342,000 after acquiring an additional 1,855,419 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Pfizer by 22.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock worth $1,101,713,000 after purchasing an additional 6,977,587 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Pfizer by 0.6% in the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock worth $486,762,000 after purchasing an additional 100,900 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PFE. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They set an "underperform" rating and a $25.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Evercore ISI upgraded Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Finally, Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and a consensus target price of $32.00.

Pfizer Trading Down 0.7 %

Shares of PFE stock traded down $0.19 on Friday, hitting $26.30. The company had a trading volume of 35,146,711 shares, compared to its average volume of 35,869,448. The stock's 50-day moving average is $26.08 and its two-hundred day moving average is $27.99. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $149.06 billion, a P/E ratio of 35.55, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the previous year, the business earned ($0.17) earnings per share. Pfizer's revenue for the quarter was up 31.2% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer's dividend payout ratio is presently 232.43%.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the business's stock in a transaction dated Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company's stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.